Dr. John Cush RheumNow
3 years 5 months ago
Conaghan shares unpublished data from PROMOTE study at #RNL2023
Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this--
https://t.co/Zfh7CbqvPi https://t.co/kIYKRFtUX2
Dr. John Cush RheumNow
3 years 5 months ago
Metanalysis of 38 studies(458,256 pts). Diabetes was seen in 19% of hyperuricemic and 16.7% of gout pts - an even higher DM prevalence was seen in North America (20.7%) https://t.co/AYVWaditxG https://t.co/T4fedCSpx1
Dr. John Cush RheumNow
3 years 5 months ago
Matched cohort study of 67,598 German primary care Pts shows gout have incr risk of breast cancer (4.5% gout vs 3.7% non-gout; HR: 1.17; 1.05-1.31). Association only seen under age 50 (HR: 1.58; 1.10-2.27), but notin women over 50 yrs https://t.co/pl6gH2GyZQ https://t.co/VR8kuumhNv
Dr. John Cush RheumNow
3 years 5 months ago
What happens to PsA in pregnancy?
1/3 with mod-severe disease
Little evidence of change of disease activity in pregnancy
Disease may increase post-partum
Christina Chambers @mothertobaby
#RNL2023 @RheumNow https://t.co/0QAxhHb45u https://t.co/zb0YSaqiOf
Dr. John Cush RheumNow
3 years 5 months ago
DMARDs/TNF for PMR:
MTX- initial benefit, but no 5 year steroid sparing effect
Infliximab - no benefit
Lef - some benefit in case series
Robert Spiera #RNL2023 @RheumNow https://t.co/d7BpmxFfct https://t.co/jLJDPuMtD3
Dr. John Cush RheumNow
3 years 5 months ago
Is there role for MTX in GCA
Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse
BUT: limitations of meta-analysis, short follow-up, dose response not evaluated
Robert Spiera at #RNL2023 @RheumNow https://t.co/lucAWypvr7 https://t.co/W604xXesaI
Dr. John Cush RheumNow
3 years 5 months ago
#RNL2023
Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications"
No prospective studies, 2 large retrospective studies suggesting benefit
@RheumNow https://t.co/V8C43LN5wl https://t.co/2focIzWhPP
Dr. John Cush RheumNow
3 years 5 months ago
Lit review of 2236 articles found only 28 w/ Post-COVID autoimmune Dx (64% F; age 51 yrs) - that included 11 (39) IIM (w/ 4 DM); 7 (25%) SLE; 4 (14%) anti-synthetase syndrome; 4 (14%) SSc; 1 lupus/MCTD overlap. Mean onset 23.7 d post COVID https://t.co/jtRaqIBGH1 https://t.co/WilcRFNAL9
Dr. John Cush RheumNow
3 years 5 months ago
Review of the etiology of Polyserositis (14 pts, 23 articles): most common - neoplasia (26.3%; Lung Lymphoma; ovarian; pancreatic), autoimmune (16.7% - SLE, AOSD) & infections (12.3%; coxackie, CMV, mTB). https://t.co/Bubd99ETgu https://t.co/VbiPB0y7pv
Dr. John Cush RheumNow
3 years 5 months ago
Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis
Analysis of patient data from five Nordic registries shows that the uptake of newer b/tsDMARDs in PsA was mainly in biologic-experienced patients.
https://t.co/SP9ZKGvM0J https://t.co/1tfSiWHYfl
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally, presenting with pulmonary symptoms (asthma), eosinophilia and granulomatous or vasculitic involvement of several organs. A multidisciplinary,
Fibromyalgia patients hoping to see a more effective and convenient formulation of cyclobenzaprine at their local pharmacies must wait for an ongoing phase III trial -- the product's third -- to finish, as the first two delivered mixed results.
